“Simbiter Omega” Multiprobiotic: A New Aid in Treatment of Generalized Chronic Periodontitis

Mykytenko AO1, Yankovskiy DS2, Dyment GS2, Beregova TV3 and Neporada KS*1
1Ukrainian Medical Dental Academy, Poltava, Ukraine
2“O.D. Prolisok” scientific production company, Kyiv, Ukraine
3The Institute of Biology, Taras Shevchenko National University of Kyiv, Kyiv, Ukraine

Abstract

Contemporary treatment of generalized chronic periodontitis is based on elimination of periodontal pathogens by antibiotics and antiseptics after local scaling and administration of cytoprotectors, immunomodulators and osteotrophic drugs for oral rehabilitation. Current concept distinguishes three levels of protection: the biofilm, which normally should be in dynamic equilibrium of competitive antagonism of periodontal pathogens and symbiotic normoflora; a natural barrier, presented by oral mucosa epithelium; the system of general and tissue immunity. Under certain circumstances, degradation of one of the protective layer leads to imbalance and total insufficient protection. Consequently, we hypothesize that such therapy will result in destruction of the first protective layer, i.e., oral microbiota microbiocenosis imbalance. Therefore, monotherapy with “Simbiter omega” multiprobiotic is the effective supplement for common therapy, since it promotes restoration of all oral mucosa protective layers against the background of antagonist fighting of colonies of Bifidobacterium, Lactobacillus, Streptococcus, Propionibacterium and Acetobacter with periodontal pathogens Actinobacillus swarmingcomitans, Porphyromonas gingivalis, Bacteroides forsythus mainly. Omega-3 and omega-6 essential polyene fatty acids and smectite, containing in multiprobiotic, have synergizing parodontoprotective effect.

Keywords: Multiprobiotic; Probiotic; Periodontitis; Smectite; Omega-3 essential polyene fatty acid

Introduction

The new era of periodontal microbiology began when Socransky S.S. and Haffajee A.D. (1992) proposed the new “formula” for periodontitis lesions. The essence of the concept was that periodontal disease is the complicated pathophysiological process, involving several factors: bacterial pathogens, sensible organism, imbalances of normal oral microflora and periodontal host response [1-3]. Consequently, oral dysbiosis is recognized as one of the main pathogenetic factors, leading to periodontitis. We hypothesize that treatment of inflammatory periodontal diseases may be effective in dysbiosis correction. Currently, the problem of microecologic disturbances is becoming global and, subsequently, there is a need in highly effective agents of antidysbiosis therapy. The demand for such products promoted avalanche-like enlargement of assortment, but, unfortunately, not all biocenose-regenerative agents are effective. The effective agent in treatment of periodontitis should possess the following properties. Firstly, the microorganism cultures are to be living and not lyophilized, in sufficient amount, as once they were entered to oral cavity, there is no time for activation, since the factors of periodontal pathogens aggression will immediately start eliminating them. Secondly, only mutual symbiosis with saccharolytic microorganisms can promote manifestation of rather efficient therapeutic effect as different levels of acidity, oxidation-reduction potential, content of oxygen, carbonic acids and nutrients are sustained in different regions of the oral cavity. Consequently, different regions of the oral cavity are populated with specific microbial associations for which the existent conditions are the most preferable [2]. Thirdly, microorganisms are to be competitive with periodontal pathogens as for receptors for adhesines at the surface of the microorganism cells. Fourthly, the agent should contain an effective enterosorbent in case of oral microbiota microbiocenosis imbalance. Sixthly, it should be of cytoprotective action with respect to host cells. Probiotics of VII generation meets all these criteria. “Simbiter omega” multiprobiotic is one of the representatives of such agents. The study was aimed at clinical and biomedical validation of the effectiveness of “Simbiter omega” multiprobiotic administration to become a
supplementary aid for the treatments of generalized chronic periodontitis.

**Methods**

The clinical and periodontal parameters of subjects were assessed by a single examiner. The clinical diagnosis of generalized chronic periodontitis was based on the presence of up to 30% of measured sites with Clinical Attachment Loss (CAL) > 5 mm [4]. 56 patients (mean age 35-42 years) have been involved into clinical study. The patients have been divided into following groups: 20 apparently healthy individuals were assigned into group I; patients with generalized chronic periodontitis of I-II degree in the remission period were assigned into group II. Patients from the main (II) group have undergone professional oral hygiene with subsequent prescription to use “Simbiter omega” multiprobiotic in dentoalveolar trays that resemble mouth guards overnight for 20 days. Dentoalveolar trays have reservoirs at marginal gingiva for direct contact of agent’s symbiotic microflora with oral biofilm. They were made of polyethylene by the “Ultraform” dental vacuum composer (Figure 1).

“Simbiter omega” multiprobiotic has been developed by the “O.D. Prolisok” scientific production company, and is the new form of “Simbiter” group multiprobiotic of the VII generation. It comprises of 18 strains of probiotic bacteria that belong to Bifidobacterium, Lactobacillus, Lactococcus, Streptococcus, Propionibacterium groups and Acetobacter, and are in the form of steady mutual symbiosis. The base of the multiprobiotic is a high-purity smectite (bentonite) gel, which is a natural clay polymermineral composition, 60-70% consisting of minerals from the montmorillonite group. Adsorbing and ion-exchange properties of smectites are considered to be the main factors of their therapeutic effect. The multiprobiotic has a positive effect on vital functions of saccharolytic obligate anaerobes, constituting its bacterial base, and human physiological microbiocoenosis. It also promotes the increase of microflora’s resistance to difficult environments [5]. Additionally, the multiprobiotic consists of flax and wheat sprouts oils, which are the valuable source of Omega-3 and Omega-6 essential polyene fatty acids. They reveal their cytoprotective and regulatory properties in the human body by restoration of the cytoderm and synthesis of mediators. Probiotic activity of the agent is determined by the high antagonistic activity relative to wide range of pathogenic and opportunistic microorganisms, synthesis of vitamins, short-chain fatty acids, exopolysaccharides, glycopeptides, etc. The “Simbiter omega” multiprobiotic contains not less than 2 x 10^10 live cells of probiotic bacteria in one doze (10 cm^3) and is indicated to children above 3 years old and adults. One doze (10 cm^3) of “Simbiter omega” contains concentrated biomass of microorganisms’ symbiosis live cells: lactobacilli and lactooccci (not less 1.0 X 10^10 CFU/cm^3), propionic-acid bacteria (not less 1.0 X 10^9 CFU/cm^3), bifdus bacteria (not less 1.0 X 10^10 CFU/cm^3), vinegar bacteria (not less 1.0 X 10^6 CFU/cm^3).

To estimate objectively the condition of periodontal tissues in patients of all groups the Fedorov-Volodkina’s (1971) hygienic index (HI), Parma (1960) modification Papillary-Marginal-Alveolar (PMA) index, gingival index (Schiller-Pisarev’s test), Russel’s (1956) Periodontal Index (PI), Mьhlemann and Mazor (1985) Sulcus Bleeding Index (SBI) have been calculated; Ketschke’s test has been made to detect pus in periodontal recesses and the depth of periodontal recesses has been measured by the graduated probe; the degree of pathological tooth mobility has been determined [6].

Unstimulated oral fluid, collected from the patients on an empty stomach has been biochemically examined to measure the volume of oxidation-modified proteins [7], TBA-reactants [8], catalase [9] and superoxide dismutase [10] activity. The degree of endogenous intoxication has been determined by the volume of intermediate mass molecules [11]; proteinase-inhibitory potential has been measured through proteinase activity [12] and total antitryptic activity [13], ornithine decarboxylase activity [14].

Microbiological analysis of substance, withdrawn from periodontal recess was carried out by sterile pin # 30. Hereafter it was placed into hermetic container with the environment for preserving anaerobic microflora and delivered to the laboratory. Microbiological studies of periodontal recess’s volume have

---

**Figure 1:** Study cast for manufacturing custom-made dentoalveolar tray with reservoir at the marginal gingiva to form a deposit zone.
“Simbiter Omega” Multiprobiotic: A New Aid in Treatment of Generalized Chronic Periodontitis

Copyright: © 2015 Neporada et al.

been performed at Kharkiv I. I. Mechnikov Research Institute of Microbiology and Immunology of Ministry of Public Health of Ukraine in compliance with methodological guidelines [15].

During the test for distributional adequacy the Shapiro-Wilk’s calculation criterion was applied. If the data corresponded to the normal distribution, then the authenticities of their differences, while comparing the mean values, were determined using the Student’s t-criterion. In the case when data series were not subject to normal distribution, the statistical processing has been carried out using the Mann-Whitney’s distribution-free method.

Results

The significant improvement of clinical indices used to estimate parodontal status in patients with generalized chronic periodontitis has been noted after prophylactic treatment with “Simbiter omega” multiprobiotic, as shown in Figure 2. The Fedorov-Volodkina’s hygienic index, PMA gingival index, periodontal index and Sulcus Bleeding Index (SBI) were significantly changed in all patients after treatment as compared to the rates before “Simbiter omega” multiprobiotic administration (Figure 2).

Consequently, use of “Simbiter omega” multiprobiotic by all patients with generalized chronic periodontitis leads to inhibition of oxidative stress along with the increase of oral fluid antiradical protection.

Intermediate mass molecules reflect the degree of endogenous intoxication [11]. It has been revealed that the volume of intermediate mass molecules was significantly increased in oral fluid of patients with generalized chronic periodontitis. The volume of intermediate mass molecules has been significantly reduced in oral fluid of patients, administered with “Simbiter omega” multiprobiotic, as compared to the values before treatment (Figure 3).

Findings of microbiological examination, shown in Figure 3, stated a significant reduction of periodontal pathogens after treatment, indicating about the clinical effectiveness of “Simbiter omega” multiprobiotic.

In conclusion, overnight administration of “Simbiter omega” multiprobiotic, applied under individual dentoalveolar caps, is the effective adjunctive therapy for patients with generalized chronic periodontitis, proved by the proteinase-inhibitory potential normalization, increased activity of ornithinedecarboxylase and inhibition of free radical oxidation along with antiradical protection of oral fluid.

Discussion

The objective estimation of proteolysis system is only possible in conditions of consideration of total proteolytic activity of oral fluid and proteinase inhibitors activity, which inhibits proteolytic enzymes and its ratio, is determined as proteinase-inhibitory potential.

Matrix Metallo Proteinases (MMPs) produced by immune regulatory cells and fibroblasts play a destructive role in the inflammatory periodontal lesion progression. It has been proven that HtrA1 plays a novel role in process of periodontal damage as proteolytic protein [3].

It has been established that total proteolytic activity significantly increased in oral fluid of all patients before treatment of generalized chronic periodontitis, whereas total antityptic activity was decreasing. Therefore, the progression of generalized chronic periodontitis causes imbalance of oral fluid proteinase-inhibitory potential. Administration of multiprobiotic
promoted significant decrease of total proteolytic activity in oral fluid along with significant increase of total antitryptic activity in patients after treatment as compared to the values before treatment (Table 1).

Ornithinedecarboxylase is the key enzyme in synthesis of such regulatory polyamines as putrescine, spermine, spermidine, etc., which regulate the replication and transcription processes and, consequently, proliferation of cells. There is also evidence of the role of polyamines, related to ornithinedecarboxylase, in the Vascular Endothelial Growth Factor (VEGF) action mechanism [16,17]. *In vitro* studies show that polyamines stimulate the activity of DNA-dependent RNA-polymerase. Polyamines significantly initiate synthesis of peptides by changing the conformation of ribosomes. Consequently, polyamines play an important regulatory role in the processes related to biosynthesis of proteins and nucleic acids.

It has been established that ornithinedecarboxylase activity significantly decreased in oral fluid of all patients before treatment of generalized chronic periodontitis, as compared to control. After treatment ornithinedecarboxylase activity significantly increased in oral fluid of patients, who were administered with “Simbiter omega” multiprobiotic in dentoalveolar trays overnight, as compared to the activity of the enzyme before treatment (Table 1).

In sum, clinical efficacy of “Simbiter omega” multiprobiotic has been proved on the ground of proteinase-inhibitory potential investigation and ornithinedecarboxylase activity in oral fluid of patients with generalized chronic periodontitis with evidence of significant decrease of proteinase activity along with increase of activity of proteinase inhibitors and ornithinedecarboxylase. Admittedly, activation of processes of free radical oxidation is the universal mechanism of cell damage in stress situations [18,19], ischemia and during post-ischemic period [20]. Lipid peroxidation products are recognized as one of the strongest modifiers of biological membranes in the range of pathological processes. They are able to increase the penetrability of lipid bilayer for K⁺, H⁺ and Ca²⁺ ions, change its physicochemical properties, leading to reduction of membrane fluidity, charge rate, causing the lipid-protein interaction disorder, inactivation of integral proteins [20].

The findings of integral indices of free radical oxidation of volume of oxidation-modified proteins and TBA-reactants in oral fluid during progression of generalized chronic periodontitis and treatment with “Simbiter omega” multiprobiotic are shown in Figure 3.

Intensification of free radical oxidation in oral fluid has been noted in all patients with generalized chronic periodontitis, which is indicated by significant increase of volume of oxidation-modified proteins and TBA-reactants. Administration of “Simbiter omega” multiprobiotic promotes significant decrease of volume of oxidation-modified proteins and TBA-reactants in oral fluid as compared to the values before treatment (Figure 3).

Catalase is one of the main enzymes of antiradical protection, able to inactivate peroxide, and is the synergist of superoxide dismutase; hence, estimation of its activities is important in...
evaluation of body antioxidant system. It has been established that activity of catalase and superoxide dismutase in oral fluid is significantly decreased in patients with generalized chronic periodontitis. A significant increase of catalase and superoxide dismutase in oral fluid of all patients with generalized chronic periodontitis has been noted after treatment with “Simbiter Omega” multiprobiotic, as compared to the values before treatment (Figure 3).

References

11. Gabrielyan NI, Lipatova VI. Actual experience with index of

Table 1: Biochemical values of oral fluid of patients with generalized chronic periodontitis of I–II degree during the remission before and after preventive treatment with “Simbiter Omega” Multiprobiotic and control (M±m).

<table>
<thead>
<tr>
<th>No</th>
<th>Value</th>
<th>Before treatment (n=36)</th>
<th>After treatment (n=36)</th>
<th>Control group (n=20)</th>
<th>Statistic value</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Ornithinedecarboxylase activity, mmol/ml*min</td>
<td>23.64 ± 1.15</td>
<td>30.9 ± 1.11</td>
<td>34.47 ± 0.53</td>
<td>P&lt;0.05</td>
</tr>
<tr>
<td>2</td>
<td>Catalase activity, µcat/l</td>
<td>0.13 ± 0.0067</td>
<td>0.29 ± 0.0099</td>
<td>0.32 ± 0.0044</td>
<td>P&lt;0.05</td>
</tr>
<tr>
<td>3</td>
<td>Total proteolytic activity , µg/ml*min</td>
<td>18.03 ± 0.13</td>
<td>13.7 ± 0.49</td>
<td>11.4 ± 0.44</td>
<td>P&lt;0.05</td>
</tr>
<tr>
<td>4</td>
<td>Total antitryptic activity, g/l</td>
<td>2.44 ± 0.16</td>
<td>4.42 ± 0.08</td>
<td>5.03 ± 0.03</td>
<td>P&lt;0.05</td>
</tr>
<tr>
<td>5</td>
<td>NOS activity, µmol/l*min</td>
<td>3.33 ± 0.31</td>
<td>6.13 ± 0.16</td>
<td>6.41 ± 0.45</td>
<td>P&lt;0.05</td>
</tr>
<tr>
<td>6</td>
<td>Amount of NO₂, µmol/l</td>
<td>6.72 ± 0.29</td>
<td>7.81 ± 0.35</td>
<td>8.11 ± 0.15</td>
<td>P&lt;0.05</td>
</tr>
<tr>
<td>7</td>
<td>Volume of oxygen modified proteins, a.u.</td>
<td>0.12 ± 0.0047</td>
<td>0.06 ± 0.0021</td>
<td>0.05 ± 0.0028</td>
<td>P&lt;0.05</td>
</tr>
<tr>
<td>8</td>
<td>Volume of TBA-reactants, µmol/l</td>
<td>64.64 ± 7.79</td>
<td>40.47 ± 1.47</td>
<td>36.54 ± 0.75</td>
<td>P&lt;0.05</td>
</tr>
<tr>
<td>9</td>
<td>Superoxide dismutase activity, u/g</td>
<td>0.12 ± 0.0039</td>
<td>0.18 ± 0.0019</td>
<td>0.19 ± 0.0019</td>
<td>P&lt;0.05</td>
</tr>
<tr>
<td>10</td>
<td>Intermediate mass molecules, a.u.</td>
<td>0.2 ± 0.0064</td>
<td>0.11 ± 0.0054</td>
<td>0.1 ± 0.0042</td>
<td>P&lt;0.05</td>
</tr>
</tbody>
</table>


